Tempus AI Sees Unusually Large Options Volume (NASDAQ:TEM)

Tempus AI, Inc. (NASDAQ:TEM) saw unusually large options trading activity on Tuesday. Stock investors bought 43,297 call options on the company. This is an increase of approximately 601% compared to the average daily volume of 6,178 call options.

Analysts Set New Price Targets

A number of research firms have recently weighed in on TEM. Bank of America increased their price objective on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research note on Friday, December 13th. Wolfe Research began coverage on shares of Tempus AI in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target on the stock. Needham & Company LLC reiterated a “buy” rating and set a $56.00 price objective on shares of Tempus AI in a research note on Tuesday, January 14th. Loop Capital decreased their price target on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday, January 14th. Finally, Guggenheim started coverage on Tempus AI in a research note on Monday, December 9th. They set a “buy” rating and a $74.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.36.

Insider Buying and Selling

In other Tempus AI news, major shareholder Bradley A. Keywell sold 395,800 shares of the firm’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total value of $16,999,610.00. Following the completion of the transaction, the insider now owns 16,164,449 shares of the company’s stock, valued at approximately $694,263,084.55. This trade represents a 2.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Eric P. Lefkofsky sold 187,655 shares of the business’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $37.54, for a total value of $7,044,568.70. Following the sale, the chief executive officer now owns 9,557,283 shares in the company, valued at approximately $358,780,403.82. The trade was a 1.93 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,300,761 shares of company stock valued at $51,271,197 over the last 90 days.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. First Horizon Advisors Inc. purchased a new position in Tempus AI in the third quarter worth approximately $30,000. FNY Investment Advisers LLC acquired a new stake in Tempus AI during the 4th quarter worth $67,000. Sandia Investment Management LP purchased a new position in shares of Tempus AI during the second quarter worth about $136,000. Vestor Capital LLC acquired a new position in shares of Tempus AI in the third quarter valued at approximately $153,000. Finally, Stifel Financial Corp purchased a new position in Tempus AI during the 3rd quarter worth $218,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Stock Up 5.9 %

TEM opened at $50.45 on Thursday. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The business has a fifty day simple moving average of $44.42 and a 200-day simple moving average of $47.41. Tempus AI has a 52 week low of $22.89 and a 52 week high of $79.49.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.